PR Newswire Clinical TrialsOriginal article
Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
RegulatoryapprovedYochanra®Positive
AI Analysis
Summary
TransThera Sciences' Yochanra® becomes the first China-developed drug to address acquired resistance to FGFR inhibitor therapy in cholangiocarcinoma patients, making its global debut in China on August 6, 2026.
Outcome Details
First innovative drug developed in China to address FGFR inhibitor resistance; global debut in China
Importance:7/10
Sentiment:
0.85
ChinaFGFR inhibitorcholangiocarcinomadrug resistanceregulatory approvalinnovation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 7, 2026 6:44 AM